Introduction
Myasthenia gravis (MG) is a prototypic autoimmune disease commonly associated with thymic pathology. Among MG patients, those with a thymoma (paraneoplastic MG) differ from others by a lack of significant human leukocyte antigen (HLA) association, absence of gender preponderance, and a poor response to thymectomy. There is also much evidence that paraneoplastic MG (p-MG) has a pathogenesis different from the more common thymic lymphofollicular hyperplasiaassociated MG. 1 Defective central tolerance probably contributes to the pathogenesis of p-MG that occurs in about 30% of the patients with thymomas. These epithelial neoplasms generate and export many T cells, but self-tolerance induction is apparently defective in thymomas because of low human leukocyte antigen (HLA) class II expression 2 in a disorganized micro-environment with an undetectable expression of the Autoimmune Regulator (AIRE). 3 Previously, we reported a paradoxical predisposition to p-MG by the cytotoxic T-lymphocyte-associated protein 4 (CTLA4) high-expressing genotype þ 49A/A-although it protects against several other autoimmune diseases. 4 That, in turn, implies a unique pathogenesis, with high CTLA4 levels similarly favoring the escape of non-tolerant CD4( þ ) T cells from MG( þ ) thymomas.
Both CTLA4 and protein tyrosine phosphatase, non-receptor type 22 (PTPN22), are potent inhibitors of T-cell activation. Their presumed low-expression or low-activity genotypes predispose to multiple autoimmune diseases, including type 1 diabetes, [5] [6] [7] [8] [9] Graves' disease, 7, 8 hypothyroidism, 6, 8 systemic lupus erythematosus, 6, 10 rheumatoid arthritis, 6, 11 and non-thymoma myasthenia gravis (MG). 12 However, the function of PTPN22 in this tolerance failure 13 has become debatable because of the paradoxically stronger inhibition of T-cell activation 14 by the autoimmunity-prone PTPN22 þ 1858T/T ( 620 W) or C/T genotype rather than the protective þ 1858C/C ( 620 R). A previous study on French subjects showed an association of the PTPN22 þ 1858C/T single nucleotide polymorphism with non-thymoma MG without anti-titin antibodies but not with thymoma-associated MG. 12 It has been found that interleukin-2 (IL-2) is expressed in the thymus during T-cell receptor (TCR)-mediated thymocyte apoptosis, and IL-2/IL-2 receptor (IL-2R) signaling is required for intrathymic negative selection of T cells. 15 To pursue the function of PTPN22 in T-cell selection and thymoma-associated MG, we analyzed the PTPN22 þ 1858C/T single nucleotide polymorphism in a total of 426 German Caucasian individuals, including 125 thymoma patients (79 with MG and 46 without MG), 129 non-thymoma early-onset MG (EOMG) patients, and 172 healthy control subjects. The intratumorous IL-2 mRNA expression level was also studied in 39 thymoma patients (24 with MG and 15 without MG).
Results

PTPN22 þ 1858C/T genotypes
The results of PTPN22 genotyping are shown in Table 1 . We observed no deviations from Hardy-Weinberg equilibrium in any group. The gain-of-function- Lack of interaction between the MG-prone PTPN22 and CTLA4 genotypes In a previous study, we found that the CTLA4 high genotype þ 49A/A was significantly more common in MG( þ ) than in MG(À) thymomas. 4 On testing for interactions between PTPN22 þ 1858T( þ ) and CTLA4 þ 49A/G genotypes, we did not find a significant synergistic genetic effect when comparing MG( þ ) thymoma patients and control subjects by logistic regression (P ¼ 0.29; OR ¼ 2.04; 95% CI 0.54-7.63).
Thirteen MG( þ ) thymoma patients (16.5%) had both MG-associated genotypes (CTLA4 þ 49A/A and PTPN22 þ 1858T( þ )); this combination was seen in only two of the MG(À) thymoma patients (4.3%; P ¼ 0.089 vs MG( þ ) thymoma) and only in 9 of the 172 healthy controls (5.2%; P ¼ 0.0070 vs MG( þ ) thymoma; OR ¼ 0.28; 95% CI 0.11-0.69). Nevertheless, 33 (41.8%) of the 79 MG( þ ) thymoma patients had neither of the two susceptibility genotypes.
In EOMG, our previous study showed no CTLA4 associations. 4 Now the PTPN22 þ 1858T( þ ) associations proved to be equally significant regardless of the CTLA4 þ 49A/G genotype (data not shown). Logistic regression also showed no evidence of interactions between PTPN22 þ 1858T( þ ) and CTLA4 þ 49A/A in EOMG (P ¼ 0.77; OR ¼ 1.19; 95% CI 0.37-3.85).
IL-2 expression in thymomas
Using quantitative RT-PCR, with the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as reference, we found significantly lower IL-2 expression within the whole cohort of thymomas with PTPN22 þ 1858T( þ ) genotypes ( Figure 1a ; P ¼ 0.028). Significantly lower IL-2 expression was also found in the MG( þ ) thymomas with PTPN22 þ 1858T( þ ) (n ¼ 10; relative IL-2 levels 0.55±0.40 (mean and 95% CI)) compared with À1858T(À) genotypes (n ¼ 14; IL-2 levels 1.80±0.84, respectively) (P ¼ 0.014). A similar but nonsignificant trend (P ¼ 0.60) was also observed in MG(À) thymomas: IL-2 expression was 0.85±1.05 in the PTPN22 þ 1858T( þ ) subgroup (n ¼ 4), and 1.62 ± 1.57 in the þ 1858T(À) sub-group (n ¼ 10). This IL-2 expression did not correlate with the patient's MG status, histological type or CTLA4 þ 49A/G genotype (Figures 1b-d 
Discussion
Our results show an association of the gain-of-function PTPN22 þ 1858T( þ ) genotypes with thymoma-associated MG, but no significant synergy with the previously implicated CTLA4 high þ 49A/A genotype. Genotype and allele frequencies did not differ significantly between females and males.
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The þ 1858T allele of PTPN22 encodes a 620 W variant, and predisposes to several autoimmune diseases. [5] [6] [7] [9] [10] [11] These now include EOMG, 12, 16 as confirmed here. PTPN22 is mainly expressed in lymphocytes, in which it physically associates with Csk kinase, an important suppressor of Src family kinases, which mediate TCR signaling. By disrupting the action of Csk, PTPN22 is one of the most potent inhibitors of T cell activation. 5 Although initially predicted to promote T-cell activation, 5 the autoimmunity-prone þ 1858T ( 620 W) variant surprisingly confers greater inhibition; that is, þ 1858T( þ ) instead defines a dominant gain-of-function variant in T cells. 14 This seemingly paradoxical situation parallels our previous observation on a distinctive CTLA4 þ 49A/A bias in thymoma MG patients. 4 The resulting T17A substitution leads to an increased surface CTLA4 expression, 17 and hence inhibits T-cell activation. 18 Although protective in other autoimmune diseases, this allele was associated with MG among thymoma patients. 4 We proposed that the key difference in thymomas is related to their unique biology: although 490% of MG(À) thymomas almost completely lack terminally mature CD4 þ thymocytes, most MG( þ ) thymomas generate and export substantial numbers of mature, autoreactive CD4 þ T cells. [19] [20] [21] In this unique 'black-and-white' setting, the CTLA4 high þ 49A/A genotype might contribute to the observed survival of autoreactive CD4( þ ) thymocytes that develop in MG( þ ) thymomas by impairing their TCR signaling during negative selection, and thus interfering in central tolerance induction. 4 Indeed, the latter hypothesis is supported by CTLA4 knockout mice: although these mice generate mature thymocytes in a virtually normal thymus and develop a lymphoproliferative disease outside the thymus due to unopposed TCR/CD28 signaling in mature T cells, intrathymic negative selection of immature thymocytes is strengthened compared with CTLA4 high wild-type mice.
22,23
Figure 1 Intra-thymoma interleukin-2 (IL-2) expression level (relative to GAPDH; mean and 95% confidence interval) is significantly lower in thymomas with PTPN22 (protein tyrosine phosphatase, non-receptor type 22) þ 1858T( þ ) genotypes (a). The expression did not correlate with myasthenia gravis status, histological type or CTLA4 (cytotoxic T-lymphocyte-associated protein 4) þ 49A/G genotype (b, c, d). A clear trend of lower IL-2 expression in PTPN22 þ 1858T( þ ) cases was observed in both the lymphocyte-poor (World Health Organization (WHO) types A and B3) thymomas and the lymphocyte-rich (WHO types AB and B2) thymomas (e, f).
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By analogy, we hypothesize that the gain-of-function PTPN22 þ 1858T( þ ) genotypes that associate with p-MG also impair tolerogenic signaling in these thymomas. This interpretation is supported by our finding of reduced IL-2 expression in thymomas with PTPN22 þ 1858T( þ ) genotypes, including the cohort of MG þ thymomas. IL-2 is involved in TCR-mediated thymocyte apoptosis, and IL-2/IL-2R signaling is required for intrathymic negative selection. 15 The lower IL-2 expression in thymomas with PTPN22 þ 1858T( þ ) genotypes again suggests weaker TCR signaling and reduced deletion of autoreactive T cells. Furthermore, the PTPN22-encoded lymphoid-specific phosphatase is strongly expressed in both murine 24 and human 25 thymus, modulates TCR signaling in thymocytes 25 and targets several thymocyte proteins with an established or presumed role in central tolerance. 26 Our hypothesis could explain the predisposition by these gain-of-function PTPN22 and CTLA4 variants that we observed in MG patients with thymomas.
There is discrepancy between our findings and those of two previous studies from France and Sweden 12,16 that did not show PTPN22 associations with thymoma MG. Although one of the cohorts (47 cases) might have been underpowered in detecting the true impact of PTPN22 genotypes on MG development in thymomas, 16 this argument does not apply to the other study that included roughly the same number (n ¼ 80) of MG( þ ) thymoma patients 12 as ours. One possibility could be subtle differences between the (Caucasian) patients studied. Furthermore, the proportions of different histological thymoma types were not reported in the previous studies.
12, 16 Although we did not find that the PTPN22 þ 1858C/T genotype correlated with thymoma histological type, the number of cases per thymoma histological type was too small to safely exclude an impact of histological type on the correlation with PTPN22 genotypes. Finally, none of the studies mentioned the number of thymomas with intratumorous lymphofollicular hyperplasia. This feature is virtually pathognomonic for MG in a substantial minority of thymomas, 27 which could hint to another level of genetic diversity among MG-associated thymomas and should be taken into account in future case-control studies assessing polymorphisms in thymomas.
It may seem surprising that prevalence of the gain-offunction PTPN22 genotypes ( þ 1858T( þ ) (C/T or T/T)) was increased in p-MG and EOMG patients alike. However, three recent observations suggest that autoimmunizing pathomechanisms in these MG subgroups might be more similar than assumed so far. First, in EOMG patients, evidence for central tolerance failure has been provided by the analysis of a promoter polymorphism in the acetylcholine receptor a-subunit (AChRa) gene and expression levels of the autoimmune regulator AIRE that both critically modulate tolerogenic AChRa expression levels in the thymic medulla. 28 Second, broad autoantibody profiles showed an unexpected extent of overlap between EOMG and p-MG patients. 3 Third, Lefvert et al. 16 recently showed in a heterogeneous cohort of 100 MG patients (including patients with EOMG, lateonset MG, sero-negative MG and thymoma-associated MG) that there were increased numbers of IL-2-expressing AChR-reactive T-cells in the blood of MG patients with PTPN22 þ 1858T( þ ) genotypes. They hypothesized that, in MG, PTPN22 þ 1858T( þ ) genotypes might exceptionally render T-cells hyperactive rather than anergic (without referring to the different MG subtypes, including p-MG). However, our finding of lower IL-2 expression levels in association with PTPN22 þ 1858T( þ ) genotypes in MG( þ ) thymomas does not support this view as far as p-MG is concerned. Without having to invoke an MG-specific hypothetical switch of PTPN22 function, the increased numbers of autoreactive T-cells in the blood of MG patients might alternatively be explained by attenuated thymic negative selection due to the gain-of-function PTPN22 þ 1858T( þ ) genotypes found associated with MG 16 including p-MG as shown here. Determination of IL-2 production per cell in relation to PTPN22 þ 1858C/T genotype 14 will help to settle this issue in the various subtypes of MG including p-MG.
Taken together, these and previous 4, 19, 28 findings strongly suggest that central tolerance failure has a function in both p-MG and EOMG; we now propose that the PTPN22 þ 1858T( þ ) genotype is a new contributor to this defect.
Materials and methods
Subjects
We studied 125 thymoma patients (79 MG( þ ), 46 MG(À)), 129 non-thymoma EOMG patients with thymic lymphofollicular hyperplasia, and 172 healthy control subjects. All the MG patients had elevated serum antiAChR autoantibodies. All the subjects studied were German Caucasians. Patients with thymoma (regardless of MG status) or EOMG were randomly selected from our database, whereas the controls were healthy blood donors. All the subjects studied were checked for CTLA4 polymorphisms in our previous study. 4 One previous healthy control sample was now excluded because it proved to be a duplicate of another. The details of age, sex, and histological type of thymoma are listed in Table 2 . 4 All patients and controls were recruited after they gave their informed consent and appropriate ethics committee approval.
DNA extraction and genotyping
Genomic DNA was extracted from blood lymphocytes or frozen thymic tissue as described previously. 4 The PTPN22 þ 1858C/T genotype was identified following a previously described polymerase chain reaction/ restriction fragment length polymorphism protocol (Figure 2a ). 9 Measurement of IL-2 expression levels in thymomas We checked the intratumorous IL-2 mRNA expression level in 39 thymoma patients (24 with MG and 15 without MG). Out of the 14 PTPN22 þ 1858T( þ ) cases, 5 (35.7%) were lymphocyte-poor WHO type A or B3. In the 25 PTPN22 þ 1858T(À) cases, 10 (40%) were lymphocytepoor WHO type A or B3. Total tissue RNA was extracted from frozen thymoma tissue using TRIZOL (Sigma Aldrich, Munich, Germany). RNA purity was assessed by spectrophotometric analysis using the Nanodrop (Peqlab, Erlangen, Germany). A total of 1 mg RNA was reverse transcribed using RevertAid First Strand cDNA Synthesis Kit (Fermentas, St Leon-Roth, Germany 1C, 30 s) . The quantification was calculated using the comparative threshold cycle method (Ct) as described in the user manual of Stratagene.
Statistical analysis
The independence of alleles (Hardy-Weinberg equilibrium) in each group of individuals was checked using w 2 test. The allelic or genotypic prevalence data were compared with w 2 test calculated on 2 Â 2 contingency tables (with Yates' correction when expected numbers were o5). Differences in IL-2 expression levels between groups of patients were evaluated with the Mann-Whitney U-test. A P-value o0.05 was considered statistically significant. OR values with 95% CI were calculated to quantify differences between groups. Genetic interactions between PTPN22 and CTLA4 genotypes were checked with logistic regression using an online statistical program written by John C Pezzullo (http://statpages.org/logistic.html). 
